Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[First experience with elbasvir/grazoprevir fixed-dose combination in real-life practice in the Czech Republic].

Klinicka mikrobiologie a infekcni lekarstvi - 1 Dec 2017

Husa Petr, Husová Libuše

Abstract excerpt

Hepatitis C virus infection (HCV) is one of the leading causes of chronic liver disease worldwide. The new fixed-dose combination of the highly potent second wave first generation NS5A inhibitor elbasvir (50 mg) and the second generation protease inhibitor grazoprevir (100 mg) is contained in the drug Zepatier. This combination is indicated for the treatment of patients chronically infected with HCV genotypes 1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Benzofurans
Share to Czech Republic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Combinations

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Imidazoles

Share to Quinoxalines

Source

Identifiers

PMID: 29378382

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[First experience with elbasvir/grazoprevir fixed-dose combination in real-life practice in the Czech Republic].PMID 29378382Read ↗

Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4.Semantic proximity Read ↗

Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4.Semantic proximity Read ↗

Establishing a research production line in real-life settings: the case of Hepatitis C management in a viral hepatitis specialized Egyptian center.Semantic proximity Read ↗

Safety and efficacy of elbasvir and grazoprevir for treatment of hepatitis C.Semantic proximity Read ↗

Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study.Semantic proximity Read ↗

Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region.Semantic proximity Read ↗

Real-world effectiveness of elbasvir/grazoprevir In HCV-infected patients in the US veterans affairs healthcare system.Semantic proximity Read ↗

[Israeli guidelines for the treatment of chronic hepatitis C infection--2012 Israeli Association for the Study of the Liver].Semantic proximity Read ↗

Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials.Semantic proximity Read ↗

Preclinical and clinical properties of elbasvir (ERELSA® Tablets 50 mg) and Grazoprevir (GRAZYNA® Tablets 50 mg), novel therapeutic agents for hepatitis C.Semantic proximity Read ↗

Real-world experience of elbasvir/grazoprevir in Taiwan: This study was focused on liver and renal adverse effects.Semantic proximity Read ↗

Treatment of HCV infection in Poland at the beginning of the interferon-free era-the EpiTer-2 study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.